Dr. Jack West assesses the merits of a combination of chemotherapy with pembrolizumab (Keytruda) based on the evolving efficacy data, especially the maturing results for overall survival, with longer ...

In this weeks video, Dr. Brian GM Durie explains that even if dex gives you a boost, you should not take it daily. <br /><br />BOTTOM LINE: <br /><br />Ongoing daily use of dex is not recommended, and even weekly do...

How do you know if your MPN is progressing? Will it show in your blood work or will symptoms increase? Physician assistant, Lindsey Kalhagen, discusses progression and what might indicate a need for a...

How do you know if your MPN is progressing? Will it show in your blood work or will symptoms increase? Physician assistant, Lindsey Kalhagen, discusses progression and what might indicate a need for a...

Scott S. Tykodi, MD of Seattle Cancer Care Alliance discusses the recently released Checkmate 214 data and how favorable RCC patients may be better served staying on targeted therapies rather than imm...

Michael N. Needle, MD, and Chief Medical Officer of AVEO Oncology goes over the TIVO-1 Trial results first released in 2014. On August 28, 2017 it was announces that Tivozanib (FOTIVDA) has been appr...

How has chronic myelogenous leukemia (CML) treatment and care evolved? Dr. Michael Deininger, a leading expert, discusses ongoing research, treatment side effect management and the results of a 10-yea...

How can patients make the best treatment decisions when facing a cancer diagnosis? Join Tammy as she shares how trusting her doctor in the midst of a life-changing diagnosis raised her confidence in, ...

Patients often struggle with the decision to seek an opinion elsewhere. Is your own doctors opinion enough? Will you offend your doctor by getting a second opinion? In this segment, Dr. Brady Stein a...

Patients often struggle with the decision to seek an opinion elsewhere. Is your own doctors opinion enough? Will you offend your doctor by getting a second opinion? In this segment, Dr. Brady Stein a...

]]>
http://www.oncologytube.com/video/letting-go-of-the-guilt-physician-perspective-on-second-opinions/10002101Wed, 13 Sep 2017 19:29:34 -0700Do Patients with Advanced NSCLC Doing Well on an Immune Checkpoint Inhibitor Reach a Point of Diminishing Returns after a Fixed Duration of Treatment? (BMIC-008)http://www.oncologytube.com/video/do-patients-with-advanced-nsclc-doing-well-on-an-immune-checkpoint-inhibitor-reach-a-point-of-diminishing-returns-after-a-fixed-duration-of-treatment-bmic-008/10002100

Dr. Jack West reviews the important, clinically relevant results of the CheckMate-153 trial that asks whether there is a value in continuing an immune checkpoint inhibitor in patients with advanced NS...

Dr. Jack West summarizes the likely practice-changing results of the FLAURA trial of osimertinib vs. standard of care EGFR TKI therapy (gefitinib or erlotinib) as first line treatment for patients wit...

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. David H. Ilson argues that peri-operative chemotherapy is the standard of care.<br /><br />Earn CME Credit for a related acti...

]]>
http://www.oncologytube.com/video/debate-does-radiation-therapy-play-a-role-in-gastric-cancer-adjuvant-therapy-no/10002096Thu, 07 Sep 2017 13:14:04 -0700Debate: Is there a role for surgical management of metastatic neuroendocrine cancer? - Nohttp://www.oncologytube.com/video/debate-is-there-a-role-for-surgical-management-of-metastatic-neuroendocrine-cancer-no/10002095

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jonathan Strosberg argues that there is not a role for the surgical management of metastatic neuroendocrine cancer.<br />...

]]>
http://www.oncologytube.com/video/debate-is-there-a-role-for-surgical-management-of-metastatic-neuroendocrine-cancer-no/10002095Thu, 07 Sep 2017 13:09:37 -0700Debate: Is there a role for surgical management of metastatic neuroendocrine cancer? - Yeshttp://www.oncologytube.com/video/debate-is-there-a-role-for-surgical-management-of-metastatic-neuroendocrine-cancer-yes/10002094

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Michael A. Choti argues that there is a role for surgical management of metastatic neuroendocrine cancer.<br /><br />Earn CME...

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Zsofia K. Stadler assesses the state of knowledge regarding hereditary syndromes in GI cancer, and proffers who shoul...

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Scott Kopetz provides an update on novel therapies for GI cancers.<br /><br />Earn CME Credit for a related activity: http://...

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that the utilization of novel targets such as HER2 are not ready for prime time in the t...

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Neil H. Segal provides an update on the use of immunotherapy in the treatment of GI cancers.<br /><br />Earn CME Credit for a...

]]>
http://www.oncologytube.com/video/update-immunotherapy-in-gi-cancers/10002090Thu, 07 Sep 2017 12:16:10 -0700Update: The role of aspirin therapy in GI cancer survivors and the general populationhttp://www.oncologytube.com/video/update-the-role-of-aspirin-therapy-in-gi-cancer-survivors-and-the-general-population/10002089

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Zsofia K. Stadler provides an update on the role of aspirin therapy in both GI cancer survivors and the general popul...

Dr. Jack West explains the potential value PD-L1 expression during the initial workup of patients with advanced NSCLC, in the face of a broad FDA approval for chemo/immunotherapy regardless of PD-L1 s...

Held on 29 June 2017 in Barcelona, Spain, the Optimizing the Continuum of Care for Patients with Pancreatic Cancer symposium explored updated standards of care for treatment sequencing for pancreatic ...

In this video, Dr. Brian GM Durie explains why the risk of myeloma cells in the blood re-infused during transplant is low and unlikely to be harmful.<br /><br />BOTTOM LINE: <br /><br />Myeloma cells might be in harv...

Dr. Jack West reviews data from pivotal trials showing that platforms that enable better communication between the cancer patient and the clinic lead to better clinical outcomes, including longer over...

K. Robert Shen, MD, of the Mayo Clinic in Rochester, MN discusses how a new study highlights how estrogen could potentially be protective for some forms of cancers including esophageal cancer. <br /><br />See...

K. Robert Shen, MD of Mayo Clinic in Rochester reports that female patients with locally advanced esophageal cancer that is treated with chemotherapy and radiation therapy before surgery are more like...

Professor Gareth Thomas at the University of Southampton, United Kingdom discusses his preclinical research about cancer associated fibroblasts (CAFs) and notes that inhibiting CAFs are not sufficient...

How often should CLL testing occur, and which tests should you have? Patient Power founder and CLL patient advocate Andrew Schorr is joined by laboratory scientist Dr. Susan Leclair and CLL expert Dr....

Should you have a genetic test? MPN experts, Dr. Alison Moliterno and Dr. Stephen Oh, explain driver mutations associated with MPNs, discuss the natural mutation of genes over time and the insight gen...

]]>
http://www.oncologytube.com/video/gkt831-preclinical-model-overview-and-conclusions/10002070Wed, 30 Aug 2017 16:15:15 -0700Are Two Immunotherapy Agents Better than One? Will the MYSTIC Trial Prove to Be a Mistake? (BMIC-003)http://www.oncologytube.com/video/are-two-immunotherapy-agents-better-than-one-will-the-mystic-trial-prove-to-be-a-mistake-bmic-003/10002069

Dr. Jack West reviews the promise of combinations of immunotherapies for advanced NSCLC and the implications for the field of the initial report that the MYSTIC trial failed to show an improvement in ...

]]>
http://www.oncologytube.com/video/are-two-immunotherapy-agents-better-than-one-will-the-mystic-trial-prove-to-be-a-mistake-bmic-003/10002069Tue, 29 Aug 2017 17:38:45 -0700Early Returns on the FLAURA Trial: Should Osimertinib be a First Line Agent in EGFR Mutation-Positive NSCLC? (BMIC-002)http://www.oncologytube.com/video/early-returns-on-the-flaura-trial-should-osimertinib-be-a-first-line-agent-in-egfr-mutation-positive-nsclc-bmic-002/10002068

Dr. Jack West discusses the implications of a positive FLAURA trial, which revealed a significant improvement in progression-free survival for first line osimertinib over gefitinib or erlotinib in pat...